S. Agbo-godeau, N. -. Virelizier, E. Scotté, and F. , Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires stomatologiques (mucites, épistaxis), Bull. Cancer, vol.98, issue.3, pp.117-126, 2011.

A. Agero, S. W. Dusza, C. Benvenuto-andrade, K. J. Busam, P. Myskowski et al., Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J. Am. Acad. Dermatol, vol.55, issue.4, pp.657-670, 2006.

A. J. Armstrong, S. Halabi, T. Eisen, S. Broderick, W. M. Stadler et al., Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial, Lancet Oncol. 2016 mars, vol.17, issue.3, pp.378-388

D. Assimakopoulos, G. Patrikakos, C. Fotika, and M. Elisaf, Benign migratory glossitis or geographic tongue: an enigmatic oral lesion, Am. J. Med, vol.15, issue.9, pp.751-755, 2002.

C. Baldini, B. Duchemann, A. Hollebecque, É. Routier, A. Varga et al.,

, Mise au point sur l'inhibition de la voie Ras-MAPK : les inhibiteurs de Mek, Bull, vol.99, issue.9, pp.865-874

M. Balsat and J. Cornillon, Inhibiteurs de mTOR : de l'explication biologique à l'application thérapeutique en hématologie, Bull. Cancer (Paris), vol.98, issue.8, pp.935-943, 2011.

D. Bareti? and R. L. Williams, The structural basis for mTOR function, Semin. Cell Dev. Biol, vol.2014, pp.91-101

F. Barlesi, P. Tomasini, S. Marco, and L. Greillier, Traitements anti-angiogéniques en pratique et dans le futur en oncologie thoracique, Rev. Mal. Respir. Actual, vol.4, issue.6, pp.604-614, 2012.

E. Barrascout, J. Medioni, F. Scotte, J. Ayllon, A. Mejean et al., Inhibiteurs de l'angiogenèse : revues de l'apport thérapeutique du sorafenib, du sunitinib et du bevacizumab dans le cancer du rein métastatique, Bull. Cancer (Paris), vol.97, issue.2, pp.29-43, 2010.

C. Bédane, D. Hantz, and V. Pemphigoïde,

, Ann. Dermatol. Vénéréologie. 2011 mars, vol.138, issue.3, pp.201-208

B. Beuselinck, P. Wolter, A. Karadimou, R. Elaidi, H. Dumez et al., Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases, Br. J. Cancer, vol.107, issue.10, pp.1665-1671, 20126.

C. B. Boers-doets, J. B. Epstein, J. E. Raber-durlacher, J. Ouwerkerk, R. M. Logan et al., Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. The Oncologist, vol.17, pp.135-144, 2012.

J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med, vol.9, issue.6, pp.567-578, 2006.

J. Boonstra, P. Rijken, B. Humbel, F. Cremers, A. Verkleij et al., The epidermal growth factor, Cell Biol. Int, vol.19, issue.5, pp.413-430, 1995.

O. Bouché, E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-benmansour et al., Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires, Gastroentérologie Clin. Biol, vol.33, issue.4, pp.306-322, 2009.

W. Cacheux, L. Tourneau, C. Baranger, B. Mignot, L. Mariani et al., Thérapies ciblées dans le traitement des cancers colorectaux métastatiques : place actuelle, févr, vol.148, pp.12-19, 2011.

É. Caillot and F. Denis, Mucites radio-induites buccopharyngées : actualités sur la prise en charge. Cancer/Radiothérapie. 2012 sept, vol.16, pp.358-363

B. A. Carneiro, R. K. Ramanathan, M. G. Fakih, S. S. Krishnamurthi, B. C. Lembersky et al., Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer, Clin. Colorectal Cancer. 2012 mars, vol.11, issue.1, pp.53-59

D. L. Chan, E. Segelov, and S. Singh, Everolimus in the management of metastatic neuroendocrine tumours, Ther. Adv. Gastroenterol, vol.10, issue.1, pp.132-141, 2017.

J. Charles, C. Martel, F. De-fraipont, M. Leccia, C. Robert et al., Mécanismes de résistance aux inhibiteurs de BRAF, Ann. Dermatol. Vénéréologie, vol.141, issue.11, pp.671-681, 2014.

C. Christodoulou, A. Pervena, G. Klouvas, E. Galani, M. E. Falagas et al., Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone, Oncology, vol.76, issue.3, pp.209-211, 2009.

L. Coutte, C. Dreyer, M. Sablin, S. Faivre, and É. Raymond, Rôle de la voie PI3KAKT-mTOR dans le cancer et les thérapeutiques antitumorales, Bull. Cancer, vol.99, issue.2, pp.173-180

P. De-cremoux and J. Robert, Signalisation cellulaire et cancer : caractérisation de cibles thérapeutiques, Pathol. Biol. 2012 août, vol.60, issue.4, pp.217-222

M. J. Cross, J. Dixelius, T. Matsumoto, and L. Claesson-welsh, VEGF-receptor signal transduction, Trends Biochem. Sci, vol.28, issue.9, pp.488-494, 2003.

C. Delbaldo, S. Faivre, and R. E. , Les inhibiteurs des récepteurs de l'Epidermal Growth Factor (EGF). Rev. Médecine Interne, juin, vol.24, issue.6, pp.372-383, 2003.

G. D. Demetri, A. T. Van-oosterom, C. R. Garrett, M. E. Blackstein, M. H. Shah et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, vol.368, issue.9544, pp.1329-1338, 200614.

J. Downward, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, vol.3, issue.1, pp.11-22, 2003.

A. Duffy and S. Kummar, Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors, Target. Oncol. 2009 déc, vol.4, issue.4, pp.267-273

G. Dupic, D. Collangettes, A. Dillies, L. Calvet, O. Tournilhac et al., Ostéonécrose des maxillaires liée aux bisphosphonates et denosumab : épidémiologie, diagnostic et traitement, Bull. Cancer, vol.102, issue.12, pp.1010-1019

K. Edmonds, D. Hull, A. Spencer-shaw, J. Koldenhof, M. Chrysou et al., Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group, Eur. J. Oncol. Nurs. Off. J. Eur. Oncol. Nurs. Soc. 2012 avr, vol.16, issue.2, pp.172-184

J. Eilers and R. Million, Prevention and Management of Oral Mucositis in Patients With Cancer, Semin. Oncol. Nurs, vol.23, issue.3, pp.201-212, 2007.

J. Eilers and R. Million, Clinical Update: Prevention and Management of Oral Mucositis in Patients with Cancer, Semin. Oncol. Nurs, vol.27, issue.4, pp.1-16, 2011.

A. El-bousaadani, L. Eljahd, R. Abada, S. Rouadi, M. Roubal et al., Actualités de la prévention et du traitement des mucites orales chez les enfants cancéreux : recommandations pratiques. Cancer/Radiothérapie. 2016 mai, vol.20, pp.226-230

P. Ena, F. Chiarolini, G. M. Siddi, and A. Cossu, Oral lichenoid eruption secondary to imatinib (Glivec), J. Dermatol. Treat, vol.15, issue.4, pp.253-255, 2004.

B. Escudier, J. Bellmunt, S. Négrier, E. Bajetta, B. Melichar et al., Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, pp.2144-2150, 2010.

S. G. Fitzpatrick, S. A. Hirsch, and S. C. Gordon, The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review, J. Am. Dent. Assoc, vol.145, issue.1, pp.45-56, 1939.

C. Frémin and S. Meloche, From basic research to clinical development of MEK1/2 inhibitors for cancer therapy, J. Hematol. Oncol.J Hematol Oncol, 2010.

I. T. Gavrilovic, Y. Balagula, A. C. Rosen, V. Ramaswamy, M. N. Dickler et al., Characteristics of oral mucosal events related to bevacizumab treatment, The Oncologist, vol.17, issue.2, pp.274-278, 2012.

C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu et al., Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N. Engl. J. Med, vol.28, issue.26, pp.2733-2743, 2006.

N. Girard and F. Mornex, Sorafénib et radiothérapie dans le carcinome hépatocellulaire. Cancer/Radiothérapie. 2011 févr, vol.15, pp.77-80

R. Gonon-demoulian, J. M. Goldman, and F. E. Nicolini, Historique de la leucémie myéloïde chronique : un paradigme de traitement du cancer*. Bull. Cancer (Paris), janv, vol.101, issue.1, pp.56-67, 2014.

R. H. Goodday, Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw, Oral Maxillofac. Surg. Clin. N. Am, vol.27, issue.4, pp.527-536, 2015.

M. E. Gore, C. Szczylik, C. Porta, S. Bracarda, G. A. Bjarnason et al., Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expandedaccess trial, Lancet Oncol. 2009 août, vol.10, issue.8, pp.757-763

S. Griffin, S. Walker, M. Sculpher, S. White, S. Erhorn et al., Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck, Health Technol. Assess. Winch. Engl, vol.13, issue.1, pp.49-54, 2009.

J. Guinebretiere, Angiogenese des tumeurs. Mecanismes et deroulement, J. Radiol, vol.85, issue.9, p.1375, 2004.

N. Harbeck, C. Huang, S. Hurvitz, D. Yeh, Z. Shao et al., Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial, Lancet Oncol. 2016 mars, vol.17, issue.3, pp.357-366

I. Van-hellemond, G. J. Creemers, L. Van-warmerdam, F. A. Jong, and R. Koornstra, Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience, Clin. Oncol. 2014 mars, vol.26, issue.3, pp.135-141

R. S. Herbst, Review of epidermal growth factor receptor biology, Int. J. Radiat. Oncol, vol.59, issue.2, pp.21-26, 2004.

S. Héritier and J. Donadieu, Les inhibiteurs de BRAF et leurs applications potentielles en pédiatrie, Rev. Oncol. Hématologie Pédiatrique, vol.4, issue.2, pp.113-121, 2016.

K. Holmes, O. L. Roberts, A. M. Thomas, and M. J. Cross, Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition, Cell. Signal, vol.19, issue.10, pp.2003-2012, 2007.

T. Hubiche, B. Valenza, C. Chevreau, J. Fricain, P. D. Giudice et al., Geographic Tongue Induced by Angiogenesis Inhibitors. The Oncologist, janv, vol.4, issue.4, pp.16-17, 2013.

M. Hussain, M. Baig, H. Mohamoud, Z. Ulhaq, D. C. Hoessli et al., BRAF gene: From human cancers to developmental syndromes, Saudi J. Biol. Sci. 2015 juill, vol.22, issue.4, pp.359-373

R. N. Jorissen, F. Walker, N. Pouliot, T. Garrett, C. W. Ward et al., Epidermal growth factor receptor: mechanisms of activation and signalling, Exp. Cell Res, vol.10, issue.1, pp.31-53, 2003.

D. M. Keefe, M. M. Schubert, L. S. Elting, S. T. Sonis, J. B. Epstein et al., Updated clinical practice guidelines for the prevention and treatment of mucositis, Cancer. 2007 mars, vol.1, issue.5, pp.820-831

D. W. Kim, Y. Jung, H. Park, J. , and H. , Osteonecrosis of the jaw related to everolimus: a case report, Br. J. Oral Maxillofac. Surg. 2013 déc, vol.51, issue.8, pp.302-304

M. Klein, B. Catargi, and . Le-vegf-en-physiologie, Ann. Endocrinol, vol.68, issue.6, pp.45-56, 2007.

M. E. Lacouture, M. J. Anadkat, R. Bensadoun, B. J. Chan, A. Epstein et al., Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities, Support. Care Cancer. 2011 août, vol.1, issue.8, pp.1079-1095

K. Lanfant-weybel, T. Lequerré, and O. Vittecoq, Anti-TNF alpha dans le traitement de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante. Presse Médicale, vol.38, pp.774-787, 2009.

W. J. Lee, J. L. Lee, S. E. Chang, M. W. Lee, Y. K. Kang et al., Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br. J. Dermatol, vol.161, issue.5, pp.1045-1051, 2009.

T. Leguay, F. Mahon, . Leucémie-myéloïde-chronique, and . Emc-hématologie, , vol.2, pp.187-205, 2005.

A. Levy, L. Cleach, and L. , Lichen plan et dermatoses lichénoïdes, vol.2, pp.132-146

C. Li, S. M. Malik, B. F. Blaeser, W. J. Dehni, S. P. Kabani et al., Mucosal Pigmentation Caused by Imatinib: Report of Three Cases, Head Neck Pathol, vol.31, issue.2, pp.290-295, 2011.

A. Lièvre, E. Rouleau, B. Buecher, and E. Mitry, Intérêt clinique des mutations de BRAF dans le cancer colorectal, Bull, vol.97, issue.12, pp.1441-1452

L. Lin, P. Li, H. Chen, and L. Pang, Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor, Future Oncol. Lond. Engl. 2013 juin, vol.9, issue.6, pp.909-913

A. Lyne, A. Creedon, and B. Bailey, Mucosal pigmentation of the hard palate in a patient taking imatinib, BMJ Case Rep, 2015.

A. Maharaj, D. 'amore, and P. A. , Roles for VEGF in the adult, Microvasc. Res, vol.74, issue.2-3, pp.100-113, 2007.

F. X. Mahon, Leucémie myéloïde chronique et inhibiteurs de tyrosine kinase, vol.22, pp.894-899

F. Martins, M. A. De-oliveira, Q. Wang, S. Sonis, M. Gallottini et al., A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients, Oral Oncol. 2013 avr, vol.49, issue.4, pp.293-298

U. Mattsson, S. Halbritter, M. Serikoff, E. Christerson, L. Warfvinge et al., Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2011 mai, vol.111, pp.12-16

T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, vol.11, issue.2, pp.121-128, 2010.

R. J. Motzer, T. E. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med, vol.22, issue.8, pp.722-731, 2013.

M. Murphy and B. Stordal, Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review, Drug Resist. Updat. 2011 juin, vol.14, issue.3, pp.177-190

Y. Neuzillet, G. Karam, E. Lechevallier, and F. Kleinclauss, Inhibiteurs de mTOR : de la transplantation à l'oncologie (Revue de la littérature du Comité de Transplantation-AFU 2006). Prog. En Urol, vol.17, pp.928-933, 2007.

O. Nicolatou-galitis, M. Migkou, A. Psyrri, A. Bamias, D. Pectasides et al., Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012 févr, vol.113, pp.234-238

Z. K. Otrock, J. A. Makarem, and A. I. Shamseddine, Vascular endothelial growth factor family of ligands and receptors: Review, Blood Cells. Mol. Dis, vol.38, issue.3, pp.258-268, 2007.

A. A. Owosho, A. Blanchard, L. Levi, A. Kadempour, H. Rosenberg et al., Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients, J. Cranio-Maxillofac. Surg. 2016 mars, vol.44, issue.3, pp.265-270

K. Park, E. Tan, O. 'byrne, K. Zhang, L. Boyer et al., Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, vol.17, issue.5, pp.577-589, 2016.

J. C. Pascual, J. Matarredona, J. Miralles, V. Conesa, and J. Borras-blasco, Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases, Int. J. Dermatol, vol.45, issue.12, pp.1471-1473, 2006.

D. E. Peterson, C. B. Boers-doets, R. J. Bensadoun, and J. Herrstedt, Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up, Ann. Oncol, pp.139-151, 2015.

J. Pierga, R. Delva, X. Pivot, M. Espié, F. Dalenc et al., Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l'étude ATHENA France, Bull. Cancer, vol.101, issue.9, pp.780-788

M. Pretel-irazabal, A. Tuneu-valls, and N. Ormaechea-pérez, Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor. Actas Dermo-Sifiliográficas Engl, vol.105, pp.655-662, 2014.

T. J. Price, M. Peeters, T. W. Kim, J. Li, S. Cascinu et al., Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study, Lancet Oncol, vol.15, issue.6, pp.569-579, 2014.

D. I. Pryor, E. Burmeister, B. H. Burmeister, M. G. Poulsen, and S. V. Porceddu, Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma, Oral Oncol, vol.47, issue.10, pp.984-987, 2011.

D. I. Pryor, S. V. Porceddu, B. H. Burmeister, A. Guminski, D. B. Thomson et al., Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer, Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol, vol.90, issue.2, pp.172-176, 2009.

J. M. Purani, H. J. Purani, and . Case, Report: Treatment of geographic tongue with topical tacrolimus, BMJ Case Rep, 2014.

N. Rahimi, Vascular endothelial growth factor receptors: Molecular mechanisms of activation and therapeutic potentials, Exp. Eye Res, vol.83, issue.5, pp.1005-1016, 2006.

A. Ravaud, J. Bernhard, M. Gross-goupil, L. Digue, and J. Ferriere, Inhibiteurs de mTOR : temsirolimus et évérolimus dans le traitement du cancer du rein, Bull. Cancer (Paris), vol.97, issue.2, pp.45-51, 2010.

H. Raybaud, E. Aiem, and C. Voha, Dépistage des cancers buccaux

P. J. Roberts and C. J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene. 2007 mai, vol.14, issue.22, pp.3291-3310

U. Romeo, G. Palaia, P. J. Fantozzi, G. Tenore, and D. Bosco, A Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia. Case Rep. Dent, 2015.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. 2012 mars, vol.13, issue.3, pp.239-246

D. Rosella, P. Papi, R. Giardino, E. Cicalini, L. Piccoli et al., Medicationrelated osteonecrosis of the jaw: Clinical and practical guidelines, J. Int. Soc. Prev. Community Dent. 2016 avr, vol.6, issue.2, pp.97-104

. R. Roskoski, VEGF receptor protein-tyrosine kinases: Structure and regulation, Biochem. Biophys. Res. Commun, vol.375, issue.3, pp.287-291, 2008.

S. L. Ruggiero, T. B. Dodson, J. Fantasia, R. Goodday, T. Aghaloo et al., American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update, J. Oral Maxillofac. Surg, vol.72, issue.10, pp.1938-1956, 20141.

A. Ruppert, M. Wislez, V. Poulot, R. Lacave, M. Antoine et al., Un regard simple sur la biologie du cancer bronchique : EGFR, Rev. Mal. Respir, vol.28, issue.4, pp.565-577, 2011.

L. M. Sedger, M. F. Mcdermott, and T. Tnf, From mediators of cell death and inflammation to therapeutic giants-past, present and future, Cytokine Growth Factor Rev. 2014 août, vol.25, issue.4, pp.453-472

S. A. Soefje, A. Karnad, and A. J. Brenner, Common toxicities of mammalian target of rapamycin inhibitors, Target. Oncol. 2011 juin, vol.1, issue.2, pp.125-129

S. Sonis, N. Treister, S. Chawla, G. Demetri, and F. Haluska, Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients, Cancer, vol.1, issue.1, pp.210-215, 2010.

J. Soria, E. Felip, M. Cobo, S. Lu, K. Syrigos et al., Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial, Lancet Oncol. 2015 août, vol.16, issue.8, pp.897-907

R. St-arnaud, J. Chabot, G. Pelletier, F. Labrie, and P. Walker, Le facteur de croissance épidermique: structure, localisation, phosphorylation et régulation de son récepteur, Biochimie, vol.66, issue.7-8, pp.515-530, 1984.

S. Steinbach, T. Hummel, C. Böhner, S. Berktold, W. Hundt et al., Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.10, issue.11, pp.1899-1905, 2009.

A. Tejwani, S. Wu, Y. Jia, M. Agulnik, L. Millender et al., Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer, mars, vol.15, issue.6, pp.1286-1299, 2009.

A. Thiery-vuillemin, G. Mouillet, D. Pouessel, P. Barthelemy, C. A. Sebbagh et al., Schémas de prescription alternatif du sunitinib dans le cancer du rein métastatique: de l'underground au grand public?, Bull. Cancer, vol.101, issue.9, pp.832-840

M. Tubiana-hulin, M. Spielmann, C. Roux, M. Campone, L. Zelek et al., Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis, Crit. Rev. Oncol. Hematol, vol.71, issue.1, pp.12-21, 2009.

L. Vaillant and M. Samimi, Aphtes et ulcérations buccales. Presse Médicale. 2016 févr, vol.45, pp.215-226

E. Vigarios, C. De-bataille, M. Boulanger, J. Fricain, and V. Sibaud, Variations physiologiques de la langue, Ann. Dermatol. Vénéréologie, vol.142, issue.10, pp.583-592, 2015.

E. Vigarios, J. B. Epstein, and V. Sibaud, Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support. Care Cancer Off, J. Multinatl. Assoc. Support. Care Cancer, 2017.

A. L. Watters, J. B. Epstein, and M. Agulnik, Oral complications of targeted cancer therapies: a narrative literature review, Oral Oncol, vol.47, issue.6, pp.441-448, 2011.

A. Wells and . Egf, Int. J. Biochem. Cell Biol, vol.31, issue.6, pp.637-643, 1999.

M. Wu, A. Rivkin, T. Pham, and . Panitumumab, Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer, Clin. Ther, vol.30, issue.1, pp.14-30, 2008.

B. Yang, C. Yeh, C. Hsu, T. Chang, and C. Wang, Advanced hepatocellular carcinoma treated by a combination of sorafenib and radiotherapy, Adv. Dig. Med. 2014 mars, vol.1, issue.1, pp.25-29

J. A. Zhang, J. B. Yu, X. H. Li, and L. Zhao, Oral and Cutaneous Lichenoid Eruption with Nail Changes Due to Imatinib Treatment in a Chinese Patient with Chronic Myeloid Leukemia, Ann. Dermatol. 2015 avr, vol.1, issue.2, pp.228-229

C. Cetuximab and . For-chemotherapy-refractory, Squamous Cell Cancer of the Head and Neck

, Haute Autorité de Santé-VECTIBIX (panitumumab), anticorps monoclonal

, Haute Autorité de Santé-PERJETA (pertuzumab), anticorps monoclonal

, Haute Autorité de Santé-AVASTIN (bevacizumab), anticorps monoclonal

, Haute Autorité de Santé-AFINITOR (évérolimus)

, Cell Death and Differentiation-Tumor necrosis factor signaling, 20156.

, Haute Autorité de Santé-ZELBORAF (vemurafenib), inhibiteur de la protéine kinase BRAF

, anti MEK inhibiteur de protéine kinase

. La-muqueuse-buccale, Texte imprimé] : de la clinique au traitement, Paris : Éd. Med'com. cop, 2009.

, Table des matières

L. .. Des-figures,

L. .. Des-abréviations,

I. .. , , vol.17

C. Ses-récepteurs, , p.17

. , EGF (epidermal growth factor)

]. .. , 1.3.1 Molécules ciblant le récepteur EGFR (anticorps monoclonaux), p.22

]. .. ,

. , Pertuzumab (Perjeta®)[116]

). .. Tkis, 23 1.1.3.2.1 Gefitinib (Iressa®[117])

C. De-l'angiogenèse and V. .. Ses-récepteurs-:,

V. .. Molécules,

. Molécules and . .. Tyrosine-kinase, 31 1.2.3.2.1 Sorafenib (Nexavar®)[121]

C. .. Du-mtor, 33 1.3.1 mTOR (mammalian target of rapamicyne)

.. .. ,

C. .. Du-tnf?,

;. ]. Tnf?,

]. .. ,

. .. Molécules-anti-tnf?,

C. .. ,

B. .. ,

. Rôle-physiologique and .. .. Voies-de-signalisation,

.. .. Molécules-anti-b-raf, 5.5.2 Vemurafenib (Zelboraf®)

C. .. De-mek,

M. .. Protéine,

M. .. Molécules,

C. .. ,

;. ]. Mécanisme,

]. .. ,

B. .. Molécules,

C. .. ,

R. La-triade and . .. Opg,

. , Molécules anti RANKL : dénosumab (Prolia®, Xgeva®)

T. .. ,

M. Buccales and . .. Thérapies-ciblées,

A. .. Muqueuses,

. Mucites and . .. Stomatites,

. .. Kératoses, 65 2.1.4.1 Définition et description clinique

.. .. Langue-géographique, 67 2.1.5.1 Définition et description clinique[106]

. .. Dysgueusie,

.. .. Thérapies-ciblées,

R. , , vol.72

. .. Diagnostic-différentiel,

D. Différentiel and . .. Mucites,

D. .. ,

D. .. ,

D. .. Différentiel-kératoses,

D. Différentiel and . .. Ostéonécroses,

D. .. ,

. , Diagnostic différentiel des pathologies pigmentaires

.. .. Diagnostic-différentiel-de-la-dysgueusie,

P. Patients,

T. Par and . .. Ciblées,

E. .. Clinique-et-radiologique,

]. .. ,

]. .. ,

P. Thérapies,

P. .. ,

]. .. , 3.1.1 Prise en charge des mucites de bas grade

]. .. , OSTÉOCHIMIONÉCROSES

R. .. , , vol.101

. .. Soins-non-chirurgicaux,

. , 5.3 Soins chirurgicaux chez les patients à risque d'OCN

C. .. ,

B. .. ,

, Nancy 2017 : 123 pages, vol.34

. Th, . Chir, and . Dent, , 2017.

, Mots clés : thérapies ciblées, cancer, recommandations, prise en charge Résumé

. Pré, iidè:lll : LM. MARTRETTE-Profes.~ur de.c; Unh'e:n.ités Juges : J. GUH...LEi-T lllBAULT-MaitredeConfércnccsdcs Un1,?e. âtés F. MASCH LN Docteur en Chirurgie Oc:nrnioe P. HlRTZ-A blmll Hospitalier UnÎ\'Cr!\ht1irc

C. Kichenbrano, ~· isu1111e Ho-11>italier Universitaire Thèse pour obtenir le diplôme o~Etat <le Docteur en Chirurgie Dentaire Présentée par. l\Ionsicur FR CK EAienne

, Le 18 anar, 1986.